A Look at Bio-Rad Laboratories’s Valuation Following Precision Medicine Push and New ddPCR Platform Launches

Bio-Rad Laboratories (BIO) shares have moved higher after the company rolled out new ddPCR platforms and expanded its molecular diagnostics lineup through acquisitions and exclusive distribution deals. This signals a renewed push for growth opportunities.

See our latest analysis for Bio-Rad Laboratories.

Bio-Rad Laboratories’ recent share price has ticked up very slightly in the past week, coming on the heels of new platform launches and its push into European oncology diagnostics. Despite these new growth initiatives, the longer-term story has been challenging, with a 1-year total shareholder return just under flat and a negative 47% total return over five years. Some investors see upside in the recent progress, but sustained momentum remains uncertain as the company balances fresh opportunities with ongoing headwinds in key markets.

Given the activity around molecular testing and diagnostics, now is a perfect moment to discover other innovative names. Check out See the full list for free.

With these new platforms and partnerships in play, investors are weighing whether Bio-Rad's recent progress points to an undervalued opportunity or if the market has already factored in expectations for future growth.

Most Popular Narrative: 1.5% Undervalued

With Bio-Rad Laboratories trading at $305.49 and the narrative pointing to a fair value of $310, there is little gap between the current price and analysts’ fair value estimate. The consensus underscores some remaining optimism about future prospects, even though the premium is modest.

Recent launch and expansion of the QX Continuum and QX700 Series ddPCR platforms, alongside the acquisition of Stilla Technologies, positions Bio-Rad to accelerate its share capture as demand grows for advanced molecular diagnostics and precision medicine tools. This is expected to drive ddPCR revenue growth and improve margins through higher consumable pull-through and broader assay adoption.

Read the complete narrative.

Curious about what powers this near fair value call? Discover the unconventional growth levers and margin pivots analysts are betting on. The underlying numbers might just surprise you.

Result: Fair Value of $310 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent weakness in instrument demand and volatile healthcare reimbursement in key markets could present challenges to Bio-Rad's growth thesis going forward.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Build Your Own Bio-Rad Laboratories Narrative

If you have a different perspective or want to dig into the numbers yourself, you can craft your own take in just a few minutes, so Do it your way.

A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Unlock your next big opportunity by tapping into powerful stock screens that highlight unique growth angles, value plays, and disruptive technology trends. Don’t miss your chance to spot tomorrow’s top performers before everyone else does.

• Capture the potential of future tech by targeting these 26 quantum computing stocks, paving the way in quantum computing and transforming entire sectors with game-changing solutions.
• Secure reliable income streams when you tap into these 19 dividend stocks with yields > 3%, which consistently deliver yields above 3% and bring stability to your portfolio.
• Accelerate your growth portfolio by locking in smart opportunities among these 886 undervalued stocks based on cash flows, poised for upside based on strong cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com